RT Journal Article
SR Electronic
T1 Trajectories of host-response biomarkers and inflammatory subphenotypes in COVID-19 patients across the spectrum of respiratory support
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.28.22282858
DO 10.1101/2022.11.28.22282858
A1 Michael Lu
A1 Callie Drohan
A1 William Bain
A1 Faraaz A. Shah
A1 Matthew Bittner
A1 John Evankovich
A1 Niall Prendergast
A1 Matthew Hensley
A1 Tomeka Suber
A1 Meghan Fitzpatrick
A1 Raj Ramanan
A1 Holt Murray
A1 Caitlin Schaefer
A1 Shulin Qin
A1 Xiaohong Wang
A1 Yingze Zhang
A1 Seyed M. Nouraie
A1 Heather Gentry
A1 Cathy Kessinger
A1 Asha Patel
A1 Bernard J. Macatangay
A1 Jana Jacobs
A1 John Mellors
A1 Janet S. Lee
A1 Prabir Ray
A1 Anuradha Ray
A1 Barbara Methé
A1 Alison Morris
A1 Bryan J. McVerry
A1 Georgios D. Kitsios
YR 2022
UL http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282858.abstract
AB Purpose Enhanced understanding of the dynamic changes in the dysregulated inflammatory response in COVID-19 may help improve patient selection and timing for immunomodulatory therapies.Methods We enrolled 323 COVID-19 inpatients on different levels of baseline respiratory support: i) Low Flow Oxygen (37%), ii) Non-Invasive Ventilation or High Flow Oxygen (NIV_HFO, 29%), iii) Invasive Mechanical Ventilation (IMV, 27%), and iv) Extracorporeal Membrane Oxygenation (ECMO, 7%). We collected plasma samples upon enrollment and days 5 and 10 to measure host-response biomarkers. We classified subjects into inflammatory subphenotypes using two validated predictive models. We examined clinical, biomarker and subphenotype trajectories and outcomes during hospitalization.Results IL-6, procalcitonin, and Angiopoietin-2 were persistently elevated in patients at higher levels of respiratory support, whereas sRAGE displayed the inverse pattern. Patients on NIV_HFO at baseline had the most dynamic clinical trajectory, with 26% eventually requiring intubation and exhibiting worse 60-day mortality than IMV patients at baseline (67% vs. 35%, p<0.0001). sRAGE levels predicted NIV failure and worse 60-day mortality for NIV_HFO patients, whereas IL-6 levels were predictive in IMV or ECMO patients. Hyper-inflammatory subjects at baseline (<10% by both models) had worse 60-day survival (p<0.0001) and 50% of them remained classified as hyper-inflammatory on follow-up sampling at 5 days post-enrollment. Receipt of combined immunomodulatory therapies (steroids and anti-IL6 agents) was associated with markedly increased IL-6 and lower Angiopoietin-2 levels (p<0.05).Conclusions Longitudinal study of systemic host responses in COVID-19 revealed substantial and predictive inter-individual variability, influenced by baseline levels of respiratory support and concurrent immunomodulatory therapies.Competing Interest StatementDr. Kitsios has received research funding from Karius, Inc. Dr. McVerry has received research funding from Bayer Pharmaceuticals, Inc. and consulting fees from Boehringer Ingelheim, both unrelated to this workFunding StatementDr. Kitsios: University of Pittsburgh Clinical and Translational Science Institute, COVID-19 Pilot Award; NIH (K23 HL139987; R03 HL162655). Dr. Bain: Career Development award number IK2 BX004886 from the U.S. Department of Veterans Affairs Biomedical Laboratory R&D (BLRD) Service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We enrolled subjects following admission the hospital and obtained informed consent from the patients or their legally authorized representatives under study protocols STUDY19050099 and STUDY20040036 approved by the University of Pittsburgh Institutional Review Board (IRB).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors